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ABSTRACT 
Objective: This study aimed to analyze blood viscosity as a determining factor of ischemic stroke outcomes evaluated with National Institutes of 
Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) on day 7 and 30 post-thrombolysis.  
Methods: This study was a 4-months cohort study taking place in Cipto Mangunkusumo General Hospital from January to April 2017. Subjects were 
collected at the Emergency Department or Neurology Outpatient Department. Eligible patients gave informed consent. Patients underwent 
numerous examinations, including blood viscosity test using digital microcapillary (DM) instrument. Outcomes of patients were identified on day 7 
and day 30 post-thrombolysis using NIHSS and mRS, respectively. 
Results: Most acute ischemic stroke patients (88.6%) had blood hyperviscosity. 9.1% patients had poorer neurologic deficit on day 7 evaluated 
with NIHSS and 18.2% patients had poor outcome on day 30 evaluated with mRS. All patients with normal blood viscosity did not have a poorer 
neurologic deficit on day-7-evaluation. 
Conclusion: Blood viscosity determines the outcomes of acute ischemic stroke patients on day 7 and day 30 post-thrombolysis. 
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Stroke is the second leading cause of death and the third leading 
cause of disability [1-5]. Stroke hold accountable for 5 million deaths 
and 5 million permanent disabilities in the world [6]. Ischemic 
stroke has the highest prevalence of all types of stroke (87%) [7]. 
Stroke causes the highest mortality from the non-communicable 
disease group in Indonesia with ischemia as the main etiology [8]. In 
Indonesia, stroke prevalence is 10.9/1000 population (2018) [9].  
Blood viscosity is the blood flow resistance due to friction caused by the 
difference in the speed of blood flow movement through the lamina [10]. 
Blood viscosity is one of the components determining the flow of the 
blood. Many studies have shown a correlation between the blood flow 
and hemostasis as well as thrombosis. Blood viscosity is associated with 
the prothrombic condition [11, 12]. The blood viscosity value varies 
between individuals and may play an important role in ischemic stroke 
and transient ischemic disease (TIA) as its value is increased in some of 
those patients, 48% and 34%, respectively [13]. Blood viscosity –as part 
of the blood flow, is associated with the pathophysiology of cerebral 
ischemia. Blood hyperviscosity is found in most patients with acute 
ischemic stroke [14]. Szapary et al. study found there was an increase of 
blood viscosity in ischemic stroke patients and Meliala et al. study stated 
that blood hyperviscosity contributed as one of the stroke risk factors 
[15, 16]. Rasyid et al. and Ott et al. study found that more than 40% of 
acute ischemic stroke patients had increased blood viscosity [17, 18]. 
Blood viscosity also tends to be higher in certain populations such as 
elderly, smokers, hypertensive people, diabetic people, patients with 
ischemic heart disease, and dyslipidemic patients [11, 12, 19, 20]. Blood 
hyperviscosity contributes to the severity of the ischemic stroke 
outcomes [14, 18]. Blood hyperviscosity in the penumbra can decrease 
cerebral blood flow and lead to more severe ischemia [21]. Blood 
viscosity can be measured by the long-waiting laboratory examination or 
instantly by digital microcapillary (DM) instrument created by Al Rasyid 
in 2014 [22].  
Outcome of stroke patient can be evaluated using the National 
Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale 
(mRS). NIHSS evaluates the patient’s impairment. NIHSS can 
measure severity of symptoms related with brain infarction and 
evaluate post-stroke neurologic deficit. Higher NIHSS score 
represents more severe impairment [23]. mRS evaluates the 
patient’s disability. mRS measures patient’s independency post-
stroke [24]. This study aimed to investigate the effect of blood 
viscosity in determining the outcomes of acute ischemic stroke using 
NIHSS and mRS evaluation.  
MATERIALS AND METHODS 
Subjects and procedures 
This cohort study used consecutive sampling method of acute ischemic 
stroke patients admitted to the Emergency Department or Neurology 
Outpatient Department in Cipto Mangunkusumo General Hospital 
between January 2017 and April 2017. Inclusion criteria for this study 
were an adult (aged 19-80 y old) ischemic stroke patients with stroke 
symptom onset within 72 h. Patients with posterior circulation infarct 
(POCI) or total anterior circulation infarct (TACI) were excluded from 
this study. Patients included in this study were those who had the 
stroke for the first time. Patients with previous stroke history or/and 
had received intravenous/intra-arterial thrombolysis before were 
excluded. Patients who had chronic kidney disease, sepsis, malignancy, 
congestive heart failure, liver failure, or severe dehydration were also 
excluded; hence these factors could potentially influence the outcome 
of the therapy. Patients who consumed corticosteroid and diuretic 
were also excluded from this study. 
History taking, physical examination, and National Institute of 
Health Stroke Scale (NIHSS) score were taken on the first day 
patient came to the hospital. NIHSS score ranges between 0-42. 
Laboratory examination including blood urea, creatinine, sodium, 
potassium, and glucose level were performed on the patients. Blood 
viscosity of the patient was also investigated using digital 
microcapillary (DM) instrument. Brain imaging using commuted 
topography (CT) scan without contrast was also performed on the 
patients to establish the ischemic stroke diagnosis. 
NIHSS score of patients was taken again on day 7 hospitalized. 
Patients who had returned home before day-7-hospitalization were 
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advised to make an outpatient visit to Neurology Outpatient 
Department on day 7 post first-day-visit. NIHSS day-7 score for 
those patients was collected at that visit. All patients were told to 
make an outpatient visit on day 30 post first-day-visit to collect 
modified Rankin Scale (mRS) score. mRS score can range from 0 (no 
symptoms) to 6 (dead). NIHSS day-7 and mRS day-30 score were the 
outcomes evaluated in this study. 
Patients with NIHSS score increased ≥1 on day-7-evaluation were 
categorized as having a poorer neurologic deficit. Patients who had 
mRS day-30 score 0-2 were categorized as having good outcome 
while those who had score >2 were categorized as having poor 
outcome. 
This study also evaluated the possibility of other risk factors in 
affecting the outcomes of ischemic stroke. Risk factors investigated 
consisted of age, sex, hypertension, hyperglycemia, atrial fibrillation, 
dehydration state, and type of stroke (partial anterior circulation 
infarct [PACI] or lacunar infarct [LACI]).  
This study had been approved by Committee Ethics of Faculty of 
Medicine University of Indonesia/Cipto Mangunkusumo General 
Hospital with approval number 281/UN2/F1/ETIK/2017. All 
patients gave informed consent. Identity and data of all patients 
were held confidential. 
Statistical analysis 
Data were analyzed statistically using SPSS version 20. Most data 
were presented as categorical data. Chi-square test or Fisher’s exact 
test was performed to identify the significance of blood viscosity as a 
determining factor of ischemic stroke outcomes. The possibility of 
other risk factors in influencing outcomes of stroke was analyzed 
using logistic regression.  
RESULTS 
There were 44 ischemic stroke patients submitted to Emergency 
Department or Neurology Outpatient Department in Cipto 
Mangunkusumo General Hospital between January 2017 and April 
2017 who met the eligibility criteria and were willing to participate 
in this study. Subjects of this study: 56.8% were male; 27.3% aged 
>65 y old; 77.3% were hypertensive; 40.9% were hyperglycemic; 
6.8% had atrial fibrillation; and 47.7% had dehydration. Most 
patients (90.9%) had a lacunar infarct (LACI) type of stroke. No 
patient had fever and 88.6% patients admitted to the hospital on the 
first day of stroke symptoms onset. Fig. 1 showed that 88.6% of the 
patients had blood hyperviscosity. 
 
 
Fig. 1: Pie chart showing the percentage of blood hyperviscosity 
and nonhyperviscosity in the patients 
 
There were 39 patients with blood hyperviscosity while there were 
only 5 patients with normal blood viscosity. There was no significant 
proportional difference among other variables such as age, sex, 
hydration state, blood pressure level, blood glucose level, atrial 
fibrillation, stroke subtype, and stroke onset towards blood viscosity 
as described in table 1. 
  
Table 1: Baseline demographic and clinical characteristics of hyperviscosity and nonhyperviscosity group 
 Hyperviscosity, n (%) Non-hyperviscosity n (%) p score* Relative risk (RR) (95% CI) 
Age, y 
≤65 27 (84.4) 5 (15.6) 0.301 1.185 (1.021-1.376) 
>65 12 (100.0) 0 (0.0) 
Sex 
Male 23 (92.0) 2 (8.0) 0.638 1.093 (0.871-1.370) 
Female 16 (84.2) 3 (15.8) 
Fever 
Yes 0 (0.0) 0 (0.0) - - 
No 39 (88.6) 5 (11.4) 
Dehydration 
Yes 20 (95.2) 1 (4.8) 0.348 1.153 (0.934-1.423) 
No 19 (82.6) 4 (17.4) 
Hypertension 
Yes 30 (88.2) 4 (11.8) 1.000 0.980 (0.771-1.247) 
No 9 (90.0) 1 (10.0) 
Hyperglycemia 
Yes 14 (77.8) 4 (22.2) 0.142 0.809 (0.625-1.048) 
No 25 (96.2) 1 (3.8) 
Atrial fibrillation 
Yes 3 (100.0) 0 (0.0) 1.000 1.139 (1.016-1.277) 
No 36 (87.8) 5 (12.2) 
Stroke subtype 
PACI 3 (75.0) 1 (25.0) 0.394 0.833 (0.469-1.481) 
LACI 36 (90.0) 4 (10.0) 
Stroke onset 
Day 1 34 (87.2) 5 (12.8) 1.000 0.872 (0.773-0.983) 
Day 2-3 5 (100.0) 0 (0.0) 
*Fisher’s exact test. PACI: partial anterior circulation infarct, LACI: lacunar circulation infarct 
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Outcomes of patients 
On day-7-evaluation, only 4 patients had a poorer neurologic deficit 
than the first-day-evaluation –having increased National Institute of 
Health Stroke Scale (NIHSS) score ≥1. NIHSS score on 90.9% 
patients did not increase. Most patients (81.8%) in this study also 
had good outcome on day-30-evaluation with modified Rankin Scale 
(mRS) score 0-2 as described in fig. 2. 
 
 
Fig. 2: Column chart showing outcomes of the patients on day-7 and day-30 evaluation 
 
Factors affecting outcomes of patients 
Based on the bivariate analysis performed, partial anterior circulation 
infarct (PACI) gave a significant contribution to the poorer neurologic 
deficit (RR=10.000; 95% CI: 1.885-53.061; p=0.036, table 2). Proportion 
of poorer neurologic deficit in PACI subtype was higher than in lacunar 
infarct (LACI), 50.0% and 5.0%, respectively. Normal hydration state 
contributed to non-poorer neurologic deficit (RR=0.810; 95% CI: 0.658-
0.996; p=0.044, table 2). There were no patients with normal hydration 
state experienced poorer neurologic deficit on day-7-evaluation. 
  
Table 2: Factors affecting NIHSS score on day-7-evaluation 
 Poorer neurologic deficit 
n (%) 
Non-poorer neurologic deficit 
n (%) 
p score* Relative risk (RR) (95% CI) 
Age, y 
≤65 1 (3.1) 31 (96.9) 0.056 8.000 (0.919-69.629) 
>65 3 (25.0) 9 (75.0) 
Sex 
Male 2 (8.0) 23 (92.0) 1.000 0.760 (0.117-4.916) 
Female 2 (10.5) 17 (89.5) 
Fever 
Yes 0 (0.0) 0 (0.0) - - 
No 4 (9.1) 40 (90.9)   
Dehydration 
Yes 4 (19.0) 17 (81.0) 0.044 0.810 (0.658-0.996) 
No 0 (0.0) 23 (100.0)   
Hypertension 
Yes 3 (8.8) 31 (91.2) 1.000 0.882 (0.103-7.579) 
No 1 (10.0) 9 (90.0) 
Hyperglycemia 
Yes 2 (11.1) 16 (88.9) 1.000 1.444 (0.224-9.330) 
No 2 (7.7) 24 (92.3) 
Atrial fibrillation 
Yes 1 (33.3) 2 (66.7) 0.254 4.556 (0.657-31.572) 
No 3 (7.3) 38 (92.7) 
Stroke subtype 
PACI 2 (50.0) 2 (50.0) 0.036 10.000 (1.885-53.061) 
LACI 2 (5.0) 38 (95.0) 
Stroke onset 
Day 1 3 (7.7) 36 (92.3) 0.394 1.154 (0.738-1.805) 
Day 2-3 1 (20.0) 4 (80.0) 
*Fisher’s exact test. PACI: partial anterior circulation infarct, LACI: lacunar circulation infarct 
 
Multivariate analysis was performed to identify adjusted relative risk 
(adjusted RR) of variables fulfilling chi-square test’s conditions with p 
score <0.250 (i.e. age and stroke subtype). Logistic regression analysis 
was used. Result of the analysis showed that patients with PACI had a 
likelihood of 18.089 times to have a poorer neurologic deficit on day-7-
evaluation than patients with LACI (adjusted RR=18.089; 95% CI: 1.121-
291.970; p=0.041, table 3). Half of the patients (50.0%) with PACI had 
poorer neurologic deficit while only 5.0% patients with LACI had poorer 
neurologic deficit. Elderly patients (aged >65 y old) had a likelihood of 
9.908 times to have poorer neurologic deficit than those that younger. 
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Table 3: Determining factors of poorer neurologic deficit 
 
 
Poorer neurologic deficit 
n (%) 
Non-poorer neurologic deficit 
n (%) 
p score Adjusted RR* (95% CI) 
Stroke subtype 
PACI 2 (50.0) 2 (50.0) 0.041 18.089 (1.121-291.970) 
LACI 2 (5.0) 38 (95.0) 
Age, y 
>65 3 (25.0) 9 (75.0) 0.090 9.908 (0.698-291.702) 
≤65 1 (3.1) 31 (96.9) 
*Logistic regression analysis. PACI: partial anterior circulation infarct, LACI: lacunar circulation infarct 
 
PACI also significantly contributed to poor outcome on day-30-
evaluation (RR=10.000; 95% CI: 3.947-25.337; p=0.001, table 4). All 
patients with PACI had poor outcome while only 10.0% of patients 
with LACI had poor outcome. 
 
Table 4: Factors affecting mRS score on day-30-evaluation 
 Poor outcome, n (%) Good outcome, n (%) p score* Relative risk (RR) (95% CI) 
Age, y 
≤65 5 (15.6) 27 (84.4) 0.663 1.600 (0.450-5.688) 
>65 3 (25.0) 9 (75.0) 
Sex 
Male 4 (16.0) 21 (84.0) 0.710 0.760 (0.218-2.655) 
Female 4 (21.1) 15 (78.9) 
Fever 
Yes 0 (0.0) 0 (0.0) - - 
No 8 (18.2) 36 (81.8) 
Dehydration 
Yes 4 (19.0) 17 (81.0) 1.000 1.095 (0.313-3.835) 
No 4 (17.4) 19 (82.6) 
Hypertension 
Yes 5 (14.7) 29 (85.3) 0.355 0.490 (0.141-1.704) 
No 3 (30.0) 7 (70.0) 
Hyperglycemia 
Yes 2 (11.1) 16 (88.9) 0.439 0.481 (0.109-2.122) 
No 6 (23.1) 20 (76.9) 
Atrial fibrillation 
Yes 1 (33.3) 2 (66.7) 0.461 1.952 (0.344-11.087) 
No 7 (17.1) 34 (82.9) 
Stroke subtype 
PACI 4 (100.0) 0 (0.0) 0.001 10.000 (3.947-25.337) 
LACI 4 (10.0) 36 (90.0) 
Stroke onset 
Day 1 7 (17.9) 32 (82.1) 1.000 1.026 (0.646-1.628) 
Day 2-3 1 (20.0) 4 (80.0) 
*Fisher’s exact test. PACI: partial anterior circulation infarct, LACI: lacunar circulation infarct 
 
Table 5: Outcomes of patients with blood hyperviscosity 
 Hyperviscosity, n (%) Non-hyperviscosity, n (%) p score* Relative risk (RR) (95% CI) 
NIHSS day-7 
Poorer neurologic deficit 4 (10.3) 0 (0.0) 1.000 0.897 (0.807-0.998) 
Non-poorer neurologic deficit 35 (89.7) 5 (100.0) 
mRS day-30 
Poor outcome 7 (17.9) 1 (20.0) 1.000 0.897 (0.137-5.864) 
Good outcome 32 (82.1) 4 (80.0) 
*Fisher’s exact test. NIHSS: National Institute of Health Stroke Scale, mRS: modified Rankin Scale 
 
Impact of blood hyperviscosity on ischemic stroke outcomes 
Blood hyperviscosity significantly did not give contribution neither 
to the poorer neurologic deficit on day-7-evalution nor poor 
outcome on day-30-evaluation as described in table 5. 
DISCUSSION 
There were 44 ischemic stroke patients participated in this study. 
The patients were gathered consecutively on the outpatient visit or 
emergency department admission. 72.7% of patients aged ≤65 y old 
while 27.3% aged >65 y old. These findings do not really correspond 
with RISKESDAS 2018 stated that 45.3% people aged 65-74 y old 
had stroke and 50.2% people aged ≥75 y old had stroke [9]. These 
result probably caused by sampling method of this study. This study 
used consecutive sampling method which gathered subjects met 
eligibility criteria in the period of January 1st to April 31st 2017.  
It was found that all patients aged >65 y old had blood 
hyperviscosity. This finding corresponds with Emril et al. study 
stated that old age was associated with an increase of blood 
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viscosity. This may be due to the decrease of blood plasma volume in 
elderly which causes increased hematocrit [25].  
Most patients (56.8%) were male. This finding corresponds with 
Harris et al. and Rasyid et al. study which found the percentage of male 
ischemic stroke patients were higher than female, 59.1% vs 40.9%, 
and 63% vs 36%, respectively [26, 27]. Harris et al. and Rasyid et al. 
study both took place in Cipto Mangunkusumo General 
Hospital/Rumah Sakit Cipto Mangunkusumo (RSCM), similar with this 
study. In this study, proportion of blood hyperviscosity in male was 
higher than in female, 92.0% and 84.2%, respectively. These findings 
may be caused by higher frequency of stroke risks in male population 
such as smoking, hypertension, dyslipidemia, coronary artery disease 
(CAD), and atrial fibrillation [28, 29]. Smoking can increase blood 
viscosity by causing decrease of erythrocyte deformability and 
increase of erythrocyte aggregation [30].  
Approximately half of the patients (47.7%) had dehydration. This 
finding corresponds with Fadhly et al. study on ischemic stroke 
patients treated in RSCM during 2014 stated that 51% of the 
patients had dehydration [31]. Schrock et al. found that 36% 
patients with acute ischemic stroke had dehydration [32]. Rowat et 
al. reported that 29% of acute ischemic stroke patients had 
dehydration on the first-day hospitalized [33]. Most patients with 
dehydration in this study had blood hyperviscosity (95.2%). This 
finding corresponds with studies stated that dehydration could 
increase blood viscosity [34-36].  
Percentage of stroke risk factors i.e. hypertension, hyperglycemia, 
and atrial fibrillation was 77.3%, 40.9%, and 6.8%, consecutively. 
This finding is consistent with RISKESDAS 2013 stated that 
hypertension was the principal risk factor for stroke [8]. 
Percentages of those with blood hyperviscosity in hypertensive 
patients, hyperglycemic patients, and patients with atrial fibrillation 
in this study were high: 88.2%, 77.8%, and 100.0%, consecutively. 
These findings correspond with Kuriakose et al. study stated that 
blood hyperviscosity was present in most patients with stroke risk 
factors such as smoking, diabetes mellitus, dyslipidemia, and heart 
disease [37]. Rasyid stated that hypertension and diabetes mellitus 
can lead to blood hyperviscosity [30]. Blood viscosity increases on 
hypertensive patients [17]. In patients with diabetes mellitus, an 
increase of blood viscosity is caused by microangiopathy and/or 
macroangiopathy. A study showed that there was a significant 
correlation between increase of HbA1C level and fibrinogen level, 
erythrocyte aggregation, and blood viscosity (p<0.001) [11].  
Stroke subtype was based on Bamford’s ischemic stroke 
classification: total anterior circulation infarct (TACI); partial 
anterior circulation infarct (PACI); lacunar circulation infarct (LACI); 
and posterior circulation infarct (POCI) [38]. Ischemic stroke 
patients with TACI and POCI subtype were excluded in this study 
leaving only patients with PACI and LACI stroke subtype. Most 
patients (90.9%) had LACI. This result is consistent with Harris et al. 
study on 3627 ischemic stroke patients in Indonesia uncovered that 
45.07% of those patients had LACI stroke subtype [39]. Both 
patients with PACI and patients with LACI had high percentage of 
blood hyperviscosity, 75.0% and 90.0%, respectively. These results 
can be explained by Rasyid stated that blood hyperviscosity was 
present in most ischemic stroke cases [12, 22].  
Stroke patients selected in this study were those with symptoms onset 
within 72 h, based on study by Rasyid [22]. Onset of stroke then 
categorized as: on the first day (day 1); and on the second or the third 
day (day 2-3). Most patients (88.6%) came to the hospital on the first 
day of onset. This finding corresponds with Harris et al. study in which 
91% patients came to the hospital within 24 h of symptoms onset [40]. 
All patients who came to the hospital on day 2-3 had blood 
hyperviscosity in this study. This may be due to small number of 
patients who came to the hospital on day 2 or 3 of stroke onset (n=5). 
Most patients had favorable outcomes evaluated both on day 7 and 
day 30. On day-7-evaluation, 90.9% patients did not have poorer 
neurologic deficit. On day-30-evaluation, 81.8% had a good outcome 
with the modified Rankin Scale (mRS) score 0-2. This study followed 
an acute ischemic stroke outcome evaluation method by Rasyid and 
Smith et al. [22, 41]. Also following Rasyid study, mRS score 0-2 
were classified as good outcome while score>2 were classified as 
poor outcome [22].  
Fisher’s exact test was performed to compare percentage between 
variables. Based on test performed, there was a significant 
proportional difference between PACI and LACI towards towards 
poorer neurologic deficit on day-7-evaluation. Logistic regression 
analysis then performed. The analysis result showed that patients 
with PACI had likelihood of 18.089 times to have poorer neurologic 
deficit than patients with LACI. PACI also significantly correlated 
with poor outcome on day-30-evaluation. Patients with PACI had 
likelihood of 10 times to have poor outcome on day-30-evaluation 
than patients with LACI. These findings were consistent with Mohr 
et al. study stated that survival rate on patients with LACI was 
significantly better than another subtypes of stroke [42]. Sprigg 
study on 1484 acute ischemic stroke patients found that patients 
with LACI tend to have faster clinical improvement than patients 
with other stroke subtypes. Patients who have fast clinical 
improvement will go through early mobilization thus prevent them 
from having complications such as pneumonia and thrombosis [43].  
Nondehydration significantly contributed to non-poorer neurologic 
deficit on day-7-evaluation (RR=0.810; 95% CI: 0.658-0.996; 
p=0.044). All patients with normal hydration state had a non-poorer 
neurologic deficit. Although, both dehydration and nondehydration 
patients mostly had good outcome on day-30-evaluation, 81.0% and 
82.6%, respectively. This finding is different with Wu et al. study 
found that good mRS outcome was significantly lower in 
dehydration group of acute ischemic stroke patients (p=0.012). 
Multivariate analysis Wu et al. performed then showed that 
dehydration patients had a smaller likelihood of achieving good mRS 
outcome (score ≤2) than nondehydration patients (RR=0.46; 
p=0.004) [44]. Rowat et al. study found that dehydration was 
significantly related with poor outcomes such as death and physical 
independency (p=0.0001) [33]. Dehydration can reduce cerebral 
blood flow (CBF) and cerebral perfusion pressure (CPP) thus worsen 
ongoing ischemia and eventually lead to worse outcomes [34-36].  
Quarter of patients (25.0%) aged >65 y old had poorer neurologic 
deficit on day-7-evaluation while only 3.1% patients aged ≤65 y old 
had poorer neurologic deficit. Elderly patients (aged >65 y old) had 
likelihood of eight times to have poorer neurologic deficit than 
younger patients (RR= 8.000; 95% CI: 0.919-69.629; p=0.056). 
Multivariate analysis performed then showed that patients aged >65 
y old had tendency to have poorer neurologic deficit on day-7-
evaluation 9.908 times than patients aged ≤65 y old. Thrift et al. 
study stated that crude death rate and crude incidence rate of stroke 
were both positively correlated with the proportion of aged ≥ 65 y 
population [45]. This is most likely due to the prognosis of 
cerebrovascular disease relies on blood viscosity [46, 47]. Blood 
viscosity is increased in elderly population [30, 48]. Blood 
hyperviscosity can reduce cerebral blood flow thus causes more 
severe brain tissue hypoperfusion [46, 47].  
Blood viscosity is a major risk factor for ischemic heart disease and 
stroke [17, 49]. Autonomic activity, blood viscosity, and endothelial 
dysfunction determine the peripheral resistance. Peripheral 
resistance affects systemic blood pressure. Blood flow of the brain is 
determined by CPP that results from reduction of systemic blood 
pressure and intracranial pressure. Decrease in CBF will result in 
brain cells death. Hyperviscosity may lead to more brain cells death 
thus resulting in poorer outcome of ischemic stroke [50]. In this 
study, it was found that all patients with normal blood viscosity did 
not have poorer neurologic deficit on day-7-evaluation. Despite 
blood viscosity had been stated taking a part in determining 
outcomes of ischemic stroke in previous studies before, there was 
no significant difference of either day-7-outcome or day-30-outcome 
on patients with hyperviscosity and patients with nonhyperviscosity 
in this study. This is probably caused by small number of subjects in 
this study and there was unbalanced number of the subject between 
hyperviscosity and nonhyperviscosity group. Another limitation of 
this study is that outcome of patients on day 90 post-thrombolysis 
could not be evaluated even though it is the standard measurement 
of acute ischemic stroke patients’ functional outcome [51].  
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Results of this study suggest that blood viscosity plays a role in 
determining the outcomes of ischemic stroke. Most acute ischemic 
stroke patients had blood hyperviscosity. All patients with normal 
blood viscosity did not have a poorer neurologic deficit on day-7-
evaluation. In conclusion, blood viscosity is a determining factor of 
ischemic stroke outcomes evaluated with NIHSS and mRS on day 7 
and day 30 post-thrombolysis.  
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